StageZero Life Sciences Ltd. (SZLS.TO)
| Previous Close | 0.0400 |
| Open | 0.0400 |
| Bid | 0.0350 x N/A |
| Ask | 0.0450 x N/A |
| Day's Range | 0.0400 - 0.0400 |
| 52 Week Range | 0.0400 - 0.0900 |
| Volume | |
| Avg. Volume | 69,595 |
| Market Cap | 4.909M |
| Beta (5Y Monthly) | 0.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1700 |
| Earnings Date | May 13, 2024 - May 17, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ACCESSWIREStageZero Life Sciences Provides an Update on Application for Management Cease Trade Order
TORONTO, ON / ACCESSWIRE / April 5, 2024 /StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) ("StageZero" or the "Company"), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers ...
- ACCESSWIRE
StageZero Life Sciences Announces Delay to Fourth Quarter and Year End 2023 Financial Results
TORONTO, ON / ACCESSWIRE / April 2, 2024 /StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) ("StageZero" or the "Company"), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers ...
- ACCESSWIRE
StageZero Life Sciences, Ltd Announces Q3 2023 Financial Results and Operational Update
TORONTO, ON / ACCESSWIRE / November 15, 2023 / StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a ...
